Tempus AI

Clinical trials sponsored by Tempus AI, explained in plain language.

Tempus AI TEM NASDAQ

Healthcare technology company using AI and genomic data for precision medicine.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 8 Completed 2 Terminated 1

Targeted drug shows promise for rare genetic cancers

Disease control Stopped early

This study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…

Phase 2 • Sponsor: Tempus AI • Aim: Disease control

Last updated Jun 27, 2026 07:55 UTC

Tempus AI

Targeted drug shows promise for rare genetic cancers